An Open Label Study to Evaluate the Feasibility of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Next Previous
Trial Profile

An Open Label Study to Evaluate the Feasibility of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs CPI 613 (Primary) ; Cytarabine; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 12 Dec 2017 Results of interim analysis (n=30), presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 07 Dec 2017 According to a Rafael Pharmaceuticals media release, new data from this trial will be presented at the 2017 American Society of Hematology Annual Meeting & Exposition.
    • 23 Mar 2017 According to a Cornerstone Pharmaceuticals media release, results from the trial could potentially lead to approval for treatment of a disease that historically has been extremely difficult to treat.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top